Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PLSE vs FEMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PLSE Captures Overall Composite Edge (40.1 SELL vs 52.6 HOLD), While FEMY Leads 3–2 on Growth & Valuation Pillars

PLSE Overall Winner 6-Pillar Tally: PLSE 2 – 3 FEMY (1 Tie) Matrix Metrics: PLSE 4 – 3 FEMY

As of Nov 16, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Femasys Inc. (FEMY) on higher Unified Composite conviction (40.1/100 SELL vs. 52.6/100 HOLD) after splitting the core matrix 4–3 (led by Growth & Scale, Options & Positioning), while FEMY wins 3–2 across the 6-pillar growth and valuation breakdown. PLSE trades at $46.36 (N/M Forward P/E, -5861.2% operating margin) versus FEMY at $1.28 (N/M Forward P/E, -763.9% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. PLSE 40.1/100 SELL), PLSE captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-5861.2% vs. -763.9% operating margin) and revenue trajectory (+359.3% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: PLSE trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 40.3); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLSE vs FEMY
PLSE NASDAQ Head-to-Head Winner
Pulse Biosciences, Inc Common Stock (DE)
Surgical & Medical Instruments & Apparatus
$46.36
-8.09% 1D
Market Cap $3.7B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 1.71β · 78% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 46.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 40.3 · SMA20: $53.15 · SMA50: $51.72
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (PLSE 2 – 3 FEMY)

Columns: Metric · PLSE · FEMY
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 4.9x
2. Growth & Scale PLSE
Revenue Growth (YoY) +359.3% -18.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.5M $2.3M
Market Cap $3.7B $11.9M
3. Profitability & Quality FEMY
Gross Margin 26.8% 60.9%
Operating Margin -5861.2% -763.9%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -60.6% -425.0%
4. Balance Sheet & Cash Flow FEMY
Cash Generation (TTM) -$64M -$19M
Cash Flow Margin N/A N/A
Net Cash / Leverage $30M Net Cash -$658,045 Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PLSE
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 73.5% (10th %ile) N/A (N/A)
Put/Call OI Skew 0.70x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLSE (4) vs FEMY (3)
Institutional Metric PLSE FEMY Criterion Row Edge
Market Capitalization
Scale
$3.7B $11.9M Larger Scale PLSE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+359.3% -18.9% Higher Growth PLSE
Operating Margin (TTM)
Profitability
-5861.2% -763.9% Higher Margin FEMY
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-60.6% -425.0% Higher ROE PLSE
52-Week Range Position
Momentum
73% ($13–$59) 17% ($0–$6) Stronger Trend PLSE
Beta / 30D Volatility
Risk Regime
1.71β · 78% Vol 4.01β · 72% Vol Lower Realized Risk FEMY
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 52.6 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$1.5M $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
26.8% 60.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($30M Net Cash) -$19M (-$658,045 Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLSE +26.76 pp
PLSE: +4.34% · FEMY: -22.42%
3M Horizon PLSE +42.6 pp
PLSE: +0.78% · FEMY: -41.82%
6M Horizon FEMY +171.79 pp
PLSE: +81.02% · FEMY: +252.81%
1Y Horizon PLSE +173.08 pp
PLSE: +227.86% · FEMY: +54.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PLSE Revenue FEMY Revenue PLSE Op. Margin FEMY Op. Margin Margin Leader
FY2020 N/A $0M N/A -668.0% FEMY
FY2021 $0M $0M -4443.9% -706.7% FEMY
FY2022 $0M $0M -8293.9% -961.7% FEMY
FY2023 N/A $0M N/A -1353.4% FEMY
FY2024 N/A $0M N/A -1091.8% FEMY
FY2025 $0M $0M -21982.6% -767.0% FEMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLSE CONSOLIDATION
51d in phase · OBV NEUTRAL
Current IV 73.5%
IV Percentile 10th %ile
Put/Call OI Skew 0.70x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PLSE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLSE Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $3.7B market capitalization and -5861.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PLSE vs FEMY Key Questions & Quantitative Answers

As of Nov 16, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Femasys Inc. (FEMY) on higher Unified Composite conviction (40.1/100 SELL vs. 52.6/100 HOLD) after splitting the core matrix 4–3 (led by Growth & Scale, Options & Positioning), while FEMY wins 3–2 across the 6-pillar growth and valuation breakdown. PLSE trades at $46.36 (N/M Forward P/E, -5861.2% operating margin) versus FEMY at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. PLSE 40.1/100 SELL), PLSE captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-5861.2% vs. -763.9% operating margin) and revenue trajectory (+359.3% vs. -18.9% YoY). Technical & Structure Timing Caution: PLSE trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 40.3); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PLSE leads the Growth & Scale pillar: PLSE posts +359.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (26.8% gross margin, -5861.2% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), PLSE cumulative revenue shifted N/A while FEMY shifted N/A. In operating R&D and SG&A reinvestment, PLSE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.

FEMY screens cheaper on headline valuation multiples. PLSE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLSE (-60.6% ROE) versus FEMY (-425.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PLSE carries 73.5% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.70x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.71β · 78% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.